AKAfshin Karimzadeh

Afshin Karimzadeh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Afshin Karimzadeh has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Guardians of Sensation: Evaluating Metformin’s Power Against Chemotherapy‐Induced Neuropathy

    by Hamid Nasrolahi, Ahmad Mosalaei, Susan Andalibi, Shapour Omidvari, Mansour Ansari, Mohammad Mohammadianpanah, Niloofar Ahmadloo, Samineh Sadeghian, Afshin Karimzadeh, Ehsan Mohammad Hosseini

    Background: Chemotherapy‐induced peripheral neuropathy (CIPN) is a common and debilitating complication of cancer treatment, particularly with agents like paclitaxel. Effective preventive measures for CIPN are limited. Metformin, an antihyperglycemic agent with neuroprotective properties, has shown promise in preclinical studies; however, its clinical utility in preventing CIPN remains underexplored. Objective: This study evaluates the preventive effects of metformin on paclitaxel‐induced peripheral neuropathy in breast cancer patients. Methods: A randomized, controlled study was conducted involving 60 breast cancer patients receiving paclitaxel chemotherapy. Patients were assigned to an intervention group receiving metformin (500 mg twice daily) or a control group without metformin. Peripheral nerve function was assessed using nerve conduction studies (NCSs), measuring sensory nerve action potential (SNAP) amplitude, compound muscle action potential (CMAP) amplitude, and distal latency (DL). Clinical neurological symptoms and adverse effects of metformin were monitored throughout the study. Results: Of the 60 enrolled patients, 47 completed the study (26 control and 21 intervention). The incidence of CIPN was lower in the metformin group compared to the control group, although this difference did not reach statistical significance. Metformin was well‐tolerated, with mild gastrointestinal side effects being the most common adverse events. No significant differences between the groups were observed in SNAP amplitude, CMAP amplitude, or DL. Conclusion: Metformin may modestly reduce the incidence of CIPN in patients receiving paclitaxel chemotherapy, although the observed effect was not statistically significant. Given its safety profile and potential neuroprotective benefits, metformin warrants further investigation in larger, multicenter trials to confirm its role in CIPN prevention.


  • Electrodiagnostic signs of carpal tunnel syndrome in ocular pseudoexfoliation syndrome

    by Mansoor Shahriari, Afshin Karimzadeh, Hadi Esmaily, Saman Rezanejad, Homayoun Nikkhah, Maryam Yadgari, Asma Pourhoseingholi

    Purpose To assess the occurrence and severity of electrodiagnostic signs of carpal tunnel syndrome (ED-CTS) in patients with ocular pseudoexfoliation (PEX) and compare them with normal subjects. Method A cross-sectional study with comparison group was designed and 60 patients with PEX were recruited from May 2019 to February 2021, and the findings were compared with 59 healthy subjects. All patients underwent complete ophthalmologic examination and nerve conduction velocity test at the median nerve was used to assess the occurrence and severity of ED-CTS in both hands. Results The mean age of participants was 59.8 ± 4.5 years. Occurrence of ED-CTS was 38.3% in PEX patients and 20.3% in control subjects (P = 0.025). There was also a significant difference in the severityand presence of asymptomatic CTS (P < 0.05). Adjusting other variables, including; age and sex, having severe ED-CTS showed a 3.07fold higher chance in the PEX group (P = 0.005). Conclusion According to our finding, it seems there is a direct association between PEX and the occurrence, as well as severity of ED-CTS.

  • Open Access

    Electrodiagnostic Signs of Carpal Tunnel Syndrome in Ocular Pseudoexfoliation Syndrome: A Case-Control Study

    by Mansoor Shahriari, Afshin Karimzadeh, Hadi Esmaily, Saman Rezanejad, Homayoun Nikkhah, Maryam Yadgari, Asma Pourhoseingholi

    Purpose To assess the occurrence and severity of electrodiagnostic signs of carpal tunnel syndrome (ED-CTS) in patients with ocular pseudoexfoliation (PEX) and compare them with normal subjects.Method A 1:1 case-control study was designed and 60 patients with PEX were recruited from May 2019 to February 2021, and the findings were compared with 59 age- and gender-matched healthy controls. All patients underwent complete ophthalmologic examination and nerve conduction velocity test at the median nerve was used to assess the occurrence and severity of ED-CTS in both hands.Results The mean age of participants was 59.8 ± 4.5 years. Occurrence of ED-CTS was 38.3% in PEX patients and 20.3% in control subjects (P = 0.025). There was also a significant difference in the severity, and presence of asymptomatic CTS (P < 0.05). Adjusting other variables, including; age, sex and job difficulty, having severe ED-CTS showed a 3.49-fold higher chance in the PEX group (P = 0.002). Conclusion There is a direct relation between PEX and the occurrence, as well as severity of ED-CTS.

  • Open Access

    The comparison of the effectiveness between different doses of local methylprednisolone injection versus triamcinolone in Carpal Tunnel Syndrome: a double-blind clinical trial

    by Afshin Karimzadeh, Shahriar Bagheri, Seyed Ahmad Raeissadat, Shahab Bagheri, Seyed Mansoor Rayegani, Shahram Rahimi-Dehgolan, Farshad Safdari, Hashem Abrishamkarzadeh, Hadi Shirzad

    Purpose: Local corticosteroid injection is one of the most prevalent methods in treating carpal tunnel syndrome (CTS). However, the most efficient substance and its appropriate dosage remain controversial. In the present double-blind randomized controlled trial, the efficacy and safety of local injection of two corticosteroids (triamcinolone and methylprednisolone) were compared at two different dosages, 20 and 40 mg. Patients and methods: We consecutively included 80 patients with mild or moderate CTS and randomly assigned them to four groups: 20 or 40 mg triamcinolone (T20 or T40) and 20 or 40 mg methylprednisolone (M20 or M40) groups; each patient received a single injection of steroid using conventional approach. The four groups were relatively comparable and did not show any significant difference initially in their baseline measurements including pain intensity measured using VAS, pain-free grip strength (PFGS), nerve conduction study (NCS), and two parts of Boston Carpal Tunnel Syndrome Questionnaire: symptom severity scale (SSS) and functional status scale (FSS); the latter was our primary outcome measure. Three months after injection, they were reassessed to evaluate the clinical and electrodiagnostic changes. Results: Almost all NCS parameters, VAS, and PFGS significantly improved after treatment in all the groups (PP=0.032), while there was no significant improvement in other groups. Furthermore, SSS remarkably decreased in all the four groups, without any significant difference between the groups (P=0.87). A similar significant decrease was found in FSS, with a higher improvement in T40 group (P=0.009). There was no significant difference between the four groups in other variables after treatment. Conclusion: Based on the current data, the efficacy and safety of local injection of triamcinolone and methylprednisolone at doses of 20 and 40 mg were associated with a significant improvement in pain, functional status, and strength. Although, there was no remarkable superiority, 40 mg injection, especially for triamcinolone, yielded better NCS results and functional status